Skip to content
Back to Blog
Bio
2026-11-017 min read21

Orphan Drug Designation Gets Easier to Obtain — and Now Has a Revocation Procedure: The MFDS Notice Amendment Pre-announced on October 29 (Comments Due November 18), the Expanded Designation Criteria in Force Since February, and Designation Strategy for Pharma and Bio SMEs

On October 29, MFDS pre-announced an amendment that adds a revocation procedure for orphan drug designations, with comments due November 18. This guide covers it alongside the criteria broadened in February, and sets out how pharma and bio SMEs should apply for designation and keep it.

KITIM Consulting Team

The October 29 Pre-announcement: Writing a Revocation Procedure into the Notice

On October 29, Korea's Ministry of Food and Drug Safety (MFDS) pre-announced a partial amendment to the Regulation on Orphan Drug Designation. Comments are due by November 18. Until now, the notice has dealt mainly with who qualifies and how to apply. This amendment adds a formal revocation procedure.

  • A three-step process: receipt of a revocation request → feasibility review → notice to the companies concerned
  • During the review, MFDS may consult academic societies and patient groups, and the Central Pharmaceutical Affairs Council (CPAC) when needed
  • The notice sets out a procedure only. It does not revoke any specific product's designation
  • Press summaries leave out key details, such as who may file a request, what grounds are required and how long companies have to respond. Check the official MFDS text before drawing conclusions.

    Why a Revocation Procedure Now: Designated Products That No Longer Fit the Criteria

    In Korea, a rare disease is one with 20,000 or fewer patients, or one so hard to diagnose that its prevalence is unknown. The list of rare diseases is designated and published by the Korea Disease Control and Prevention Agency (KDCA). This year, MFDS publicly reviewed whether to revoke designations for two immune-stimulating injectables: 40 Viscum album products and 2 immunocyanin products. The CPAC advised on the matter on August 21, and industry voices raised the possibility of litigation. The debate also overlaps with drugs flagged for re-evaluation during the National Assembly audit.

    A written procedure makes revocation more predictable. It also means holders of existing designations will need to keep their evidence under continuous review.

    Meanwhile, the Bar for Designation Has Dropped: The February 2 Amendment (No. 2026-8)

    The amendment of February 2, 2026 broadened the designation criteria:

  • Products that treat or diagnose rare diseases can now be designated without proving a "significant improvement" over existing alternatives
  • Since a 2018 amendment, companies have been able to apply as early as IND approval
  • Designation can bring advantages during review, but what actually applies depends on the product and the review pathway
  • In short, designation is easier to obtain and harder to keep.

    How Pharma and Bio SMEs Should Decide Whether to Apply

    1. Confirm the target disease

    Check first whether the indication appears on the KDCA rare disease list. If it does not, you will need separate prevalence evidence.

    2. Choose the timing

  • Nonclinical stage: assemble the disease evidence and development plan
  • IND approval: the earliest point you can apply, and useful when raising investment or bidding for R&D grants
  • Before filing for approval: review the benefits of designation alongside your approval strategy
  • 3. Coordinate with designations abroad

    Reports suggest orphan drugs may get a 0% rate in the US Section 232 pharmaceutical tariff discussions. That would depend on FDA designation, which is separate from Korean designation. Export-oriented companies should plan the domestic and overseas designation timelines together.

    For Products Already Designated: Keeping the Designation

  • Monitor prevalence: a new indication or a change in diagnostic criteria can push the patient count past 20,000
  • Reassess on label changes: check whether each added or changed indication meets the orphan drug criteria on its own
  • Prepare evidence in advance: keep epidemiological data, opinions from academic societies and patient-access data on file
  • Model the impact: work out what revocation would mean for pricing, reimbursement and supply
  • Comments Due November 18: Issues for Industry to Raise

  • Who can request revocation, and on what grounds
  • Whether the response period is long enough to compile epidemiological data
  • When revocation takes effect, and what transitional rules apply to pending reviews and existing supply contracts
  • How to submit: through the MFDS legislative and administrative notice board, or through an industry association
  • How KITIM Can Help

    The Korea Institute of Technology Innovation Management (KITIM) supports:

  • Strategy and dossier preparation for orphan drug designation
  • Risk reviews for products that are already designated
  • Advice that links government R&D programs with global regulatory approval
  • If you are considering an application, or plan to comment on the amendment, contact the KITIM consulting team. We will work with you on a plan that fits your product and its stage of development.

    Orphan Drug DesignationOrphan Designation RevocationMFDS Administrative NoticeRare Disease TherapeuticsCentral Pharmaceutical Affairs CouncilPharmaceutical Regulatory AffairsBio SME

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.